France: ImCheck solidifies financial position with €96m Series C

Pierre d’Epenoux, CEO ImCheck Therapeutics

ImCheck Therapeutics, which designs and develops immunotherapeutics, has closed a €96m (US$103m) financing, co-led by Earlybird and Andera Partners. The Series C round of €80m and the last outstanding tranche of Series B converted in Series C shares (€16m) solidifies ImCheck’s financial position and leadership in the gamma-delta T cell space. Invus and The Leukemia…

You must be a HMI Subscriber to view this content.

Subscribe Now »